Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A. Greenspan SL, et al. Among authors: bone hg. Ann Intern Med. 2002 Dec 3;137(11):875-83. doi: 10.7326/0003-4819-137-11-200212030-00008. Ann Intern Med. 2002. PMID: 12458987 Clinical Trial.
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Greenspan SL, et al. Ann Intern Med. 2007 Mar 6;146(5):326-39. doi: 10.7326/0003-4819-146-5-200703060-00005. Ann Intern Med. 2007. PMID: 17339618 Clinical Trial.
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial. Eastell R, et al. Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3. Osteoporos Int. 2010. PMID: 19802508 Free PMC article. Clinical Trial.
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A. Langdahl B, et al. Among authors: bone h. J Bone Miner Res. 2012 Nov;27(11):2251-8. doi: 10.1002/jbmr.1695. J Bone Miner Res. 2012. PMID: 22777865 Free article. Clinical Trial.
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA. Black DM, et al. Among authors: bone hg. Osteoporos Int. 2013 Apr;24(4):1503-11. doi: 10.1007/s00198-012-2098-3. Epub 2012 Aug 29. Osteoporos Int. 2013. PMID: 22930240 Free PMC article. Clinical Trial.
247 results